Gyung Moon Kim

Maintenance Therapy of Facial Seborrheic Dermatitis with 0.1% Tacrolimus Ointment.

Background Topical calcineurin inhibitors (TCIs) have been successfully used to treat seborrheic dermatitis (SD) patients. Meanwhile, treatment of atopic dermatitis (AD) with low-dose, intermittent TCI has been proved to reduce disease flare-ups. This regimen is known as a maintenance treatment. Objective The aim of this trial was to investigate the efficacy and tolerability of a maintenance treatment with tacrolimus ointment in patients with facial SD. Methods During the initial stabilization period, patients with facial SD or AD applied 0.1% tacrolimus ointment twice daily for up to 4 weeks. Clinical measurements were evaluated on either in the whole face or on separate facial regions. When an investigator global assessment score 1 was achieved, the patient applied tacrolimus twice weekly for 20 weeks. We also compared our results with recent published data of placebo controlled study to allow an estimation of the placebo effect. Results The time to the first relapse during phase II was similar in both groups otherwise significantly longer than the placebo group. The recurrence-free curves of two groups were not significantly different from each other; otherwise the curve of the placebo group was significantly different. There were no significant differences between the 2 groups in the number of DEs, and treatment days for disease exacerbations (DEs). The adverse event profile was also similar between the 2 groups. During the 20 weeks of treatment, the study population tolerated tacrolimus ointment well. Conclusion The results of this study suggest that maintenance treatment with tacrolimus may be effective in preventing the occurrence of facial SD exacerbations.

Extensive partial unilateral lentiginosis

JEADV 2006, 20, 461–488

A case of Stevens–Johnson syndrome with subcorneal pustules associated with Mycoplasma pneumoniae infection

JEADV 2006, 20, 1328–1399

Fixed drug eruption mimicking supraumbilical skin rash: one of rare complication of transarterial chemoembolization

© 2008 The Authors JEADV 2009, 23, 317–368 Journal compilation

Subsequent vitiligo after hematopoietic stem cell transplantation: A nationwide population-based cohort study from Korea

Background: Subsequent vitiligo after hematopoietic stem cell transplantation (HSCT) has been described sporadically in case series. Objective: To investigate the incidence and risk factors of subsequent vitiligo after HSCT. Methods: A nationwide, population‐based cohort study was performed using the Korean National Health Insurance Claims Database from 2009 to 2013. All HSCT recipients who had undergone HSCT between 2010 and 2011 and not treatment for vitiligo in 2009 (to exclude preexisting active vitiligo) were included in the HSCT recipient group, and an age‐ and sex‐matched control group without HSCT was also established. Results: A total of 2747 HSCT recipients and 8241 controls were enrolled. Newly acquired vitiligo occurred in 1.06% of HSCT recipients between 2010 and 2013, and there was a significant increase (OR 3.130, 95% CI 1.859‐5.271) in cases of vitiligo in HSCT recipients compared with controls (0.34%). Allogeneic HSCT (OR 5.593, 95% CI 1.628‐19.213) and bone marrow‐sourced stem cells (as compared with peripheral blood‐sourced stem cells; OR 2.492, 95% CI 1.114‐5.576) were independently associated with the development of vitiligo after HSCT. Limitations: Medical record review was not available. Conclusion: Vitiligo developed at a significantly increased rate after HSCT compared with controls. Allogeneic HSCT and bone marrow–sourced stem cells were independent risk factors.

Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population‐based study

The prevalence of hidradenitis suppurativa (HS) in Asia is unknown. The associations between HS and other autoimmune disorders have rarely been reported.

A hyaluronic acid-based microneedle patch to treat psoriatic plaques: A pilot open trial.

DEAR EDITOR, Psoriasis is a common, chronic, relapsing, inflammatory skin disease characterized by multiple erythematous papules and plaques with silvery scales. It affects 0 5–3% of the world’s population. Recently, great advances have been made in the treatment of psoriasis, including the introduction of targeted biological agents. However, topical treatment remains important; most patients have mild disease affecting < 2% of the body surface area. Unfortunately, topical treatment is oily and sticky, and it takes time to reach full therapeutic effect, which results in poor patient compliance and consequently low therapeutic efficacy. The microneedle patch is a new drug delivery method that can effectively improve transdermal drug delivery. In this present study, we assessed whether a novel hyaluronic acid (HA)-based microneedle patch enhanced the therapeutic effects of topical agents in psoriasis. Ten patients with psoriatic plaques resistant to topical calcipotriol–betamethasone ointment (Daivobet ; LEO Pharma, Ballerup, Denmark) therapy for at least 4 weeks were enrolled from 1 May to 31 July 2016. One or more resistant psoriatic plaques were selected, and microneedle patches were placed over the thickest areas of the plaques after application of topical calcipotriol–betamethasone ointment. The patches were applied once daily at night for 1 week and removed the following morning. The patches were 26 9 26-mm-sized HA-

Decreased risk of vitiligo in organ transplant recipients: A population-based cohort study

To the Editor: Vitiligo remains a major challenge in dermatology because there is no definitive cure. The autoimmune nature of vitiligo has been described, and the involvement of T cells in pathogenesis of vitiligo has also been shown in previous reports. While the therapeutic potential of immunosuppressants has often been raised, their role has not been well examined. We conducted a nationwide, population-based, retrospective cohort study to investigate the risk of vitiligo in organ transplant recipients (OTRs) using Korean National Health Insurance claims database (diagnoses according to the International Classification of Diseases, 10th revision [ICD-10] code) from 2009 until 2013. We identified all OTRs with kidney (Z94.0), liver (Z94.4), heart (Z94.1), lung (Z94.2), and both heart and lung (Z94.3) transplant status, who underwent organ transplantation before 2009 and survived through 2013. OTRs who had been diagnosed with vitiligo (L80) at least once in 2009 and 2010 were excluded, to rule out preexisting vitiligo. Three controls were randomly selected for each OTR by frequency matching for age and sex among those who had not received a diagnosis of vitiligo and organ transplant status in 2009 and 2010. The outcome of interest was the 3-year risk of vitiligo, defined by a documented principal diagnosis of vitiligo (L80)

Topical evening primrose oil as a possible therapeutic alternative in children with molluscum contagiosum

5 times between 2011 and 2013 to minimize misclassification errors. Univariate and multivariate logistic regression analyses were sequentially performed to assess the risks of vitiligo in the OTR group compared to the control group. A total of 14,712 OTRs and 44,136 matched controls were enrolled. Vitiligo developed in 0.05% of OTRs between 2011 and 2013, and showed a significant decreased risk (odds ratio 0.305 [95% confidence interval 0.148e0.630]) compared with controls (0.20%; Table I). The most frequently used immunosuppressants in OTRs were tacrolimus (60.36%), mycophenolate mofetil (53.81%), and cyclosporine (42.44%; Table II). Our results may be attributed to the use of immunosuppressants in OTRs, and we speculate that the immunosuppressants could be effective in halting the spread of vitiligo as well. Although corticosteroids are the most commonly used systemic drugs for patients with spreading vitiligo, adverse effects restrict the long-term use of corticosteroids. Until now, a few case series showed conflicting results of the use of immunosuppressants other than corticosteroids for treatment of vitiligo. There are a few limitations in our study. First, the detailed information of individuals that may influence the results was not assessed, such as medications other than the immunosuppressive agents, lifestyle factors, original disease that indicated transplantation, personal/family history of vitiligo or autoimmune diseases, donorerecipient mismatch, and medical history of the donor. Second, the associations of individual drugs with vitiligo risk were not determined. In conclusion, we demonstrated the association of organ transplant status with a reduced risk of vitiligo. Although our observations do not address the effectiveness of immunosuppressants, the use of immunosuppressants might be considered to manage patients with vitiligo after reviewing the risk and benefits. Additional studies are needed.

Increased Risks of Autoimmune Rheumatic Diseases in Patients with Psoriasis: A Nationwide Population-based Study

are probably not directly related to the development of FFA, but this does not exclude a potential hormonal involvement by a local mechanism, as has been suggested previously by Tosti et al. and other authors. The limitations of our study were the retrospective design and the relatively small sample size. In conclusion, our study shows that serum hormonal levels are not consistently altered in premenopausal women diagnosed with FFA, suggesting that serum sex hormone levels are not directly implicated in the pathogenesis of this condition.